Last update 01 Nov 2024

CD16a x CD molecules x IL-21

Last update 01 Nov 2024

Basic Info

Related Targets

CD16aCD moleculesIL-21

Drugs associated with CD16a x CD molecules x IL-21

WO2023116010

Patent Mining

Target

CD molecules x CD16a x IL-21

Mechanism-

Active Org.

Shanghai Enkai Cell Technology Co., Ltd.

Originator Org.

Shanghai Enkai Cell Technology Co., Ltd.

Active Indication

Infectious Diseases

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with CD16a x CD molecules x IL-21

100 Translational Medicine associated with CD16a x CD molecules x IL-21

0 Patents (Medical) associated with CD16a x CD molecules x IL-21

Literatures (Medical) associated with CD16a x CD molecules x IL-21

01 Nov 2020·Dermatologic TherapyQ4 · MEDICINE

Investigating expression pattern of eight immune‐related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: Potential roles of CTLA4 and FCGR3A genes expression in outcomes of rituximab therapy

Q4 · MEDICINE

Article

Author: Elikaei Behjati, Somayeh ; Tavakolpour, Soheil ; Abbasi, Maryam ; Karami, Fatemeh ; Balali, Mansour ; Daneshpazhooh, Maryam ; Modarressi, Mohammad Hossein ; Balighi, Kamran ; Mahmoudi, Hamidreza ; Salehi Farid, Ali ; Masoudi, Jamileh

Pemphigus is a rare group of autoimmune diseases, which its exact molecular pathogenesis and therapeutic biomarkers remained unknown. In this regard the expressions of eight immune-related genes was evalualted in pemphigus patients. Forty-six pemphigus patients, either new case or on minimal therapy, were recruited. The expressions of IL22, IL9, IL21, EBI3, TNFSF13B, FCGR3A, CTLA4, and PDCD1 genes were analyzed at baseline, compared with 32 healthy controls, and their changes were monitored 3 months after rituximab (RTX) therapy through Reverse Transcriptase Real-time PCR (RT-Real-time PCR). Except of IL21, which was similar in both groups, expressions of other genes were significantly lower in patients compared with the controls (P-value <.05). PDCD1, EBI3, IL21, and IL22 genes were significantly overexpressed three months following RTX administration (P-value <.05). Higher prednisolone dosage and PDAI-score were positively correlated with CTLA4 and FCGR3A expressions after 3 months, respectively (P-value = .019 and .048, respectively). Anti-desmoglein 1 (Dsg 1) titer and its positivity at baseline were associated with TNFSF13B expression, FCGR3A expressions, and the PDAI-score. Our results suggest the possible involvement of some gene expressions in pemphigus immunopathogenesis, which could be affected by RTX therapy and also might be used as prognostic biomarkers.

01 Apr 2017·Immunology & Cell BiologyQ3 · MEDICINE

Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells

Q3 · MEDICINE

Review

Author: Inogés, Susana ; Perez‐Ruiz, Elisabeth ; Garasa, Saray ; Rodriguez, Inmaculada ; Berraondo, Pedro ; Melero, Ignacio ; Ochoa, Maria Carmen ; Minute, Luna

Antibody‐dependent cellular cytotoxicity (ADCC) is a set of mechanisms that target cells coated with IgG antibodies of the proper subclasses (IgG1 in the human) to be the prey of cell‐to‐cell cytolysis executed by immune cells expressing FcRIIIA (CD16A). These effectors include not only natural killer (NK) cells but also other CD16+ subsets such as monocyte/macrophages, NKT cells or γδ T cells. In cancer therapy, ADCC is exploited by antibodies that selectively recognize proteins on the surface of malignant cells. An approach to enhance antitumor activity is to act on effector cells so they are increased in their numbers or enhanced in their individual (on a cell per cell basis) ADCC performance. This enhancement can be therapeutically attained by cytokines (that is, interleukin (IL)‐15, IL‐21, IL‐18, IL‐2); immunostimulatory monoclonal antibodies (that is, anti‐CD137, anti‐CD96, anti‐TIGIT, anti‐KIR, anti‐PD‐1); TLR agonists or by adoptive infusions of ex vivo expanded NK cells which can be genetically engineered to become more efficient effectors. In conjunction with approaches optimizing IgG1 Fc affinity to CD16, acting on effector cells offers hope to achieve synergistic immunotherapy strategies.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis